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Abstract
Background: Liver × receptor a (LXRa) and b (LXRb) are members of the nuclear receptor super family of ligand-
activated transcription factors, a super family which includes the perhaps better known glucocorticoid receptor,
estrogen receptor, thyroid receptor, and peroxisome proliferator-activated receptors. There is limited evidence that
LXL activation may reduces acute lung inflammation. The aim of this study was to investigate the effects of
T0901317, a potent LXR receptor ligand, in a mouse model of carrageenan-induced pleurisy.
Methods: Injection of carrageenan into the pleural cavity of mice elicited an acute inflammatory response
characterized by: accumulation of fluid containing a large number of neutrophils (PMNs) in the pleural cavity,
infiltration of PMNs in lung tissues and subsequent lipid peroxidation, and increased production of nitrite/nitrate
(NOx), tumor necrosis factor-a, (TNF-a) and interleukin-1b (IL-1b). Furthermore, carrageenan induced the expression
of iNOS, nitrotyrosine and PARP, as well as induced apoptosis (TUNEL staining and Bax and Bcl-2 expression) in the
lung tissues.
Results: Administration of T0901317, 30 min after the challenge with carrageenan, caused a significant reduction in
a dose dependent manner of all the parameters of inflammation measured.
Conclusions: Thus, based on these findings we propose that LXR ligand such as T0901317, may be useful in the
treatment of various inflammatory diseases.
Background
Liver × receptor (LXR) is another member of the super
family of nuclear hormone receptors, which heterodi-
merizes with RXR [1]. LXR is activated by natural oxy-
sterols, such as 22(R)-hydroxycholesterol, 24,25(S)-
epoxycholesterol, and 27-hydroxycholesterol, and the
synthetic compound T0901317 [2], and regulates the
intracellular levels of cholesterol through gene induction
of enzymes and proteins involved in the cholesterol
metabolism and transport [3]. Two LXR subtypes with
different tissue distribution have been identified: LXR-a
and LXR-b.L X R - a is expressed in macrophages, liver,
spleen, kidney, adipose tissue, and small intestine [2],
whereas LXR-b is ubiquitously expressed.
In recent years, our understanding of the importance
of LXRs has expanded across several fields of patho-
physiology. Perhaps best known from a sizeable litera-
ture as homeostatic “cholesterol sensors” that drive tran-
scriptional programs promoting cellular cholesterol
efflux, “reverse cholesterol transport,” and bile acid
synthesis [4], more recent roles for LXRs in athero-
sclerosis [5], renin expression [6], glucose homeostasis
[7], innate immunity [8] and in inflammation [9-11]
have also been identified.
Various studies have clearly point out that LXRs plays a
pivotal role in innate immunity of the macrophage [10].
They inhibit macrophage apoptosis [12] and negatively
regulate proinflammatory gene expression (e.g., IL-6,
cyclooxygenase 2) induced by LPS and bacteria [13] in
macrophages, at least in part through inhibition of NF-B
[14]. LXRs and other nuclear receptors (NRs) such as glu-
cocorticoid receptor (GR) repress overlapping yet distinct
sets of proinflammatory genes [15]. Moreover, recent
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LXR modulation in inflammatory disease states may play a
role in pathogenesis [16]. Exploiting these insights, a
potential anti-inflammatory therapeutic role for synthetic
LXR agonists has recently been described in vivo in a
model of dermatitis [13], and data suggest the possibility
of therapeutic synergy among NR agonists [15].
To study whether LXR also participates in the acute
inflammatory response, mice were injected in the pleural
cavity with carrageenan to obtain an acute lung inflam-
mation, usually defined as carrageenan-induced pleurisy.
Carrageenan-induced inflammation (paw edema or
pleurisy) is a model of local acute inflammation com-
monly used to evaluate activity of anti-inflammatory
drugs [17] and useful to assess the contribution of cells
and mediators to the inflammatory process [18]. The
initial phase of carrageenan-induced pleurisy (0-1 h) has
been attributed to the release of histamine, 5-hydroxy-
tryptamine and bradykinin, followed by a late phase (1-6
h) mainly sustained by PG release due to the induction of
cyclooxygenase 2 (COX-2) in the tissues [19]. PMNs
moving out of the circulation into the inflamed tissue
have a key function in the breakdown and remodeling of
injured tissue [20,21]. Moreover, macrophages participate
in the progression of experimental pleurisy producing
pro-inflammatory cytokines such as TNFa and IL-1b.
In the present study, to explore further the possible
role of LXR in the modulation of different inflammatory
conditions in vivo, the effects of the potent LXR recep-
tor ligand T0901317, were observed on (i) polymorpho-
nuclear (PMN) infiltration (assessing myeloperoxidase
[MPO] activity), (ii) lipid peroxidation (malondialdehyde
[MDA] levels), (iii) pro-inflammatory cytokines (TNF-a
and IL-1b), (iv) nitration of tyrosine residues as an indi-
cator of peroxynitrite (by immunohistichemistry), (v)
i n d u c i b l en i t r i co x i d es y n t h a se (iNOS) expression, (vi)
NF-B expression, (vii) apoptosis (FAS-ligand and
TUNEL staining), (viii) Bax and Bcl-2 expression, and
(ix) lung damage (histology).
Methods
Animals
Male CD mice (weight 20-25 g; Harlan Nossan, Milan,
Italy) were used in these studies. The animals were
h o u s e di nac o n t r o l l e de n v i r o n m e n ta n dp r o v i d e dw i t h
standard rodent chow and water. Animal care was in
compliance with Italian regulations on the protection of
animals used for experimental and other scientific pur-
poses (D.M. 116192) as well as with EEC regulations
(O.J. of E.C. L358/1 12/18/1986).
Carrageenan-induced pleurisy
Carrageenan-induced pleurisy was induced as previously
described [22]. Mice were anaesthetized with isoflurane
and subjected to a skin incision at the level of the left
sixth intercostals space. The underlying muscle was dis-
sected and saline (0.1 ml) or saline containing 2%
l-carrageenan (0.1 ml) was injected into the pleural cav-
ity. The skin incision was closed with a suture and the
animals were allowed to recover. At 4 h after the injec-
tion of carrageenan, the animals were killed by inhala-
tion of CO2. The chest was carefully opened and the
pleural cavity rinsed with 1 ml of saline solution con-
taining heparin (5 U ml
-1) and indomethacin (10 μgm l
-1).
The exudate and washing solution were removed by
aspiration and the total volume measured. Any exudate,
which was contaminated with blood, was discarded. The
amount of exudate was calculated by subtracting the
volume injected (1 ml) from the total volume recovered.
The leukocytes in the exudate were suspended in phos-
phate-buffer saline (PBS) and counted with an optical
microscope in a Burker’s chamber after Blue Toluidine
staining.
Experimental Design
Mice were randomized into 4 groups. Sham animals
were subjected to the surgical procedure alone, receiving
a bolus injection of saline (1 ml/kg i.p.) instead of carra-
geenan, and treated 30 min after with either vehicle
(saline 1 ml/kg i.p.) or T0901317 (20, 10 and 5 mg/kg,
i.p.). The remaining mice were subjected to carragee-
nan-induced pleurisy (as described above) and treated
with an i.p. bolus of vehicle (saline1 ml/kg) or 20, 10
and 5 mg/kg T0901317. N = 10 per group. The doses of
T 0 9 0 1 3 1 7( 2 0 ,1 0a n d5m g / k g ,i . p . )u s e dh e r ew e r e
based on previous in vivo studies [23,24]
Histological examination
Lung tissues samples were taken 4 h after injection of
carrageenan. Lung tissues samples were fixed for 1 week
i n1 0 %( w / v )P B S - b u f f e r e df o r m a l d e h y d es o l u t i o na t
room temperature, dehydrated using graded ethanol and
embedded in Paraplast (Sherwood Medical, Mahwah,
NJ, USA). Sections were then deparaffinized with xylene,
stained with hematoxylin and eosin. All sections were
studied using Axiovision Zeiss (Milan, Italy) microscope.
Measurement of cytokines
TNF-a and IL-1b levels were evaluated in the exudate
4 h after the induction of pleurisy by carrageenan injec-
tion as previously described [25]. The assay was carried
out using a colorimetric commercial ELISA kit (Calbio-
chem-Novabiochem Corporation, Milan, Italy).
Measurement of nitrite-nitrate concentration
Total nitrite in exudates, an indicator of nitric oxide
(NO) synthesis, was measured as previously described
[26]. Briefly, the nitrate in the sample was first reduced
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ml) and b-nicotinamide adenine dinucleotide 3’-phos-
phate (NADPH) (160 μM) at room temperature for 3 h.
The total nitrite concentration in the samples was then
measured using the Griess reaction, by adding 100 μlo f
Griess reagent (0.1% w/v) naphthylethylendiamide dihy-
drochloride in H2O and 1% (w/v) sulphanilamide in 5%
(v/v) concentrated H3PO4; vol. 1:1) to the 100 μl sample.
T h eo p t i c a ld e n s i t ya t5 5 0n m( O D 550) was measured
using ELISA microplate reader (SLT-Lab Instruments,
Salzburg, Austria). Nitrite concentrations were calcu-
lated by comparison with OD550 of standard solutions of
sodium nitrite prepared in H2O.
Immunohistochemical localization of iNOS, IL-1b,T N F - a,
nitrotyrosine, PAR, Fas ligand, Bax and Bcl-2
At the end of the experiment, the tissues were fixed in
10% (w/v) PBS-buffered formaldehyde and 8 μms e c t i o n s
were prepared from paraffin embedded tissues. After
deparaffinization, endogenous peroxidase was quenched
with 0.3% (v/v) hydrogen peroxide in 60% (v/v) methanol
for 30 min. The sections were permeabilized with 0.1%
(w/v) Triton X-100 in PBS for 20 min. Non-specific
adsorption was minimized by incubating the section in
2% (v/v) normal goat serum in PBS for 20 min. Endogen-
ous biotin or avidin binding sites were blocked by
sequential incubation for 15 min with biotin and avidin,
respectively. Sections were incubated overnight with anti-
iNOS (1:500, Transduction Laboratories in PBS, v/v),
anti-nitrotyrosine rabbit polyclonal antibody (Upstate,
1:500 in PBS, v/v), anti-PAR antibody (BioMol, 1:200 in
PBS, v/v), anti-FAS ligand antibody (Santa Cruz Biotech-
nology, 1:500 in PBS, v/v), anti-TNF-a ligand antibody
(Santa Cruz Biotechnology, 1:500 in PBS, v/v), anti-IL-1b
ligand antibody (Santa Cruz Biotechnology, 1:500 in PBS,
v/v), anti-Bax antibody (Santa Cruz Biotechnology, 1:500
in PBS, v/v) or with anti-Bcl-2 polyclonal antibody (Santa
Cruz Biotechnology, 1:500 in PBS, v/v). Sections were
washed with PBS, and incubated with secondary anti-
body. Specific labeling was detected with a biotin-conju-
gated goat anti-rabbit IgG and avidin-biotin peroxidase
complex (Vector Laboratories, DBA).
In order to confirm that the immunoreaction for the
nitrotyrosine was specific some sections were also
incubated with the primary antibody (anti-nitrotyro-
sine) in the presence of excess nitrotyrosine (10 mM)
to verify the binding specificity. To verify the binding
specificity for iNOS, IL-1b,T N F - a,P A R ,F a sl i g a n d ,
Bax and Bcl-2, some sections were also incubated with
only the primary antibody (no secondary) or with only
the secondary antibody (no primary). In these situa-
tions no positive staining was found in the sections
indicating that the immunoreaction was positive in all
the experiments carried out.
Myeloperoxidase (MPO) activity
MPO activity, an indicator of PMN accumulation, was
determined as previously described [27]. At the specified
time following injection of carrageenan, lung tissues
were obtained and weighed, each piece homogenized in
a solution containing 0.5% (w/v) hexadecyltrimethyl-
ammonium bromide dissolved in 10 mM potassium
phosphate buffer (pH 7) and centrifuged for 30 min at
20,000 × g at 4°C. An aliquot of the supernatant was
then allowed to react with a solution of tetramethylben-
zidine (1.6 mM) and 0.1 mM hydrogen peroxide. The
rate of change in absorbance was measured spectropho-
tometrically at 650 nm. MPO activity was defined as the
quantity of enzyme degrading 1 μmol of peroxide min
-1
at 37°C and was expressed in milliunits per gram weight
of wet tissue.
Malondialdehyde (MDA) measurement
MDA levels in the lung tissue were determined as an
indicator of lipid peroxidation as previously described
[28]. Lung tissue collected at the specified time, was
homogenized in 1.15% (w/v) KCl solution. A 100 μl ali-
quot of the homogenate was added to a reaction mix-
ture containing 200 μl of 8.1% (w/v) SDS, 1.5 ml of 20%
(v/v) acetic acid (pH 3.5), 1.5 ml of 0.8% (w/v) thiobarbi-
turic acid and 700 μl distilled water. Samples were then
boiled for 1 h at 95°C and centrifuged at 3,000 × g for
10 min. The absorbance of the supernatant was mea-
sured using spectrophotometry at 650 nm.
Western blot analysis for IB-a,N F - B p65, Bax, Bcl-2,
and iNOS
Cytosolic and nuclear extracts were prepared with slight
modifications. Briefly, lung tissues from each mouse
were suspended in extraction Buffer A containing Hepes
10 mM, KCl 10 mM, EDTA 0.1 mM, EGTA 0.1 mM,
DTT 1 mM, PMSF 0.5 mM, pepstatin A 3 μg/ml, leu-
peptin 2 μg/ml, Trypsin inhibitor 15 μg/ml, Benzami-
dina 40 μM, homogenized at the highest setting for 2
min, and centrifuged at 13,000 × g for 3 min at 4°C.
Supernatants represented the cytosolic fraction. The pel-
lets, containing enriched nuclei, were re-suspended in
Buffer B containing Hepes 20 mM, MgCl2 1.5 mM,
N a C l0 . 4M ,E G T A1m M ,E D T A1m M ,D T T1m M ,
PMSF 0,5 mM, pepstatin A 3 μg/ml, leupeptin 2 μg/ml,
Trypsin inhibitor 15 μg/ml, Benzamidina 40 μM, NONI-
DET P40 1%, Glycerol 20%. After centrifugation 10 min
at 13,000 × g at 4°C, the supernatants containing the
nuclear protein were stored at -80 for further analysis.
The levels of IB-a, iNOS, Bax and Bcl-2 were quanti-
fied in cytosolic fraction from lung tissue collected 4 h
after carrageenan administration, while NF-B p65 levels
were quantified in nuclear fraction. Protein concentra-
tion in cell lysates was determined by Bio-Rad Protein
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nuclear extract from each sample was analyzed. Proteins
were separated by a 12% SDS-polyacrylamide gel elec-
trophoresis and transferred on PVDF membrane
(Hybond-P, Amershan Biosciences, UK). The membrane
was blocked with 0.1% TBS-Tween containing 5% non
fat milk for 1 h at room temperature and subsequently
probed with specific Abs IB-a (Santa Cruz Biotechnol-
ogy, 1:1000), or anti-Bax (1:500; Santa Cruz Biotechnol-
ogy), or anti-Bcl-2 (1:500; Santa Cruz Biotechnology), or
anti-iNOS (1:1000; Transduction) or anti-NF-kB p65
(1:1000; Santa Cruz Biotechnology) in 1× PBS, 5% w/v
non fat dried milk, 0.1% Tween-20 (PMT) at 4°C, over-
night. Membranes were incubated with peroxidase-con-
jugated bovine anti-mouse IgG secondary antibody or
peroxidase-conjugated goat anti-rabbit IgG (1:2000,
Jackson ImmunoResearch, West Grove, PA) for 1 h at
room temperature. To ascertain that blots were loaded
with equal amounts of proteic lysates, they were also
incubated in the presence of the antibody against b-
actin protein (1:10,000 Sigma-Aldrich Corp.) and anti-
Lamin B1 (1:10,000 Sigma-Aldrich Corp.). Protein bands
were detected with SuperSignal West Pico Chemiolumi-
nescent (PIERCE). The relative expression of the protein
bands of IB-a (~37 kDa), NF-kB p65 (~65 kDa), Bax
(~23 kDa), Bcl-2 (~29 kDa) iNOS (~130 kDa), was
quantified by densitometric scanning of the X-ray films
with GS-700 Imaging Densitometer (GS-700, Bio-Rad
Laboratories, Milan, Italy) and a computer program
(Molecular Analyst, IBM), and standardized for densito-
metric analysis to b-actin and Lamin B1 protein levels.
Terminal Deoxynucleotidyltransferase-Mediated UTP End
Labeling (TUNEL) Assay
TUNEL assay was conducted by using a TUNEL detec-
tion kit according to the manufacturer’s instructions
(Apotag, HRP kit DBA, Milan, Italy). Briefly, sections
were incubated with 15 μg/ml proteinase K for 15 min
at room temperature and then washed with PBS. Endo-
genous peroxidase was inactivated by 3% H2O2 for 5
min at room temperature and then washed with PBS.
Sections were immersed in terminal deoxynucleotidyl-
transferase (TdT) buffer containing deoxynucleotidyl
transferase and biotinylated dUTP in TdT buffer, incu-
bated in a humid atmosphere at 37°C for 90 min, and
then washed with PBS. The sections were incubated at
room temperature for 30 min with anti-horseradish per-
oxidase-conjugated antibody, and the signals were visua-
lized with diaminobenzidine.
Materials
Unless otherwise stated, all compounds were obtained
from Sigma-Aldrich Company Ltd. (Poole, Dorset, U.K.).
T0901317 was obtained from Cayman Chemical
(Michigan, USA). All other chemicals were of the high-
est commercial grade available. All stock solutions were
prepared in non-pyrogenic saline (0.9% NaCl; Baxter,
Italy, UK).
Statistical evaluation
All values in the figures and text are expressed as mean
± standard error (s.e.m.) of the mean of n observations.
For the in vivo studies n represents the number of ani-
mals studied. In the experiments involving histology or
immunohistochemistry, the figures shown are represen-
tative of at least three experiments (histological or
immunohistochemistry coloration) performed on differ-
ent experimental days on the tissue sections collected
from all the animals in each group. The results were
analyzed by one-way ANOVA followed by a Bonferroni
post-hoc test for multiple comparisons. A p-value less
than 0.05 were considered significant and individual
group means were then compared with Student’s
unpaired t test. A P-value of less than 0.05 was consid-
ered significant.
Results
Effects of T0901317 on carrageenan-induced pleurisy
When compared to lung sections taken from saline-trea-
ted animals (sham group Fig. 1a, d), histological exami-
nation of lung sections taken from mice treated with
carrageenan revealed significant tissue damage and
edema (Fig. 1b, see densitometry analysis 1d), as well as
infiltration of neutrophils (PMNs) within the tissues (see
Fig 1b1, see densitometry analysis 1d). T0901317 (20
mg/kg) reduced the degree of lung injury (Fig. 1c, d).
Furthermore, injection of carrageenan elicited an acute
inflammatory response characterized by the accumula-
tion of fluid (edema) in the pleural cavity (Table 1) con-
taining large amounts of PMNs (Table 1). Treatment
with T0901317 attenuated in a dose dependent manner
carrageenan-induced edema formation and PMN infil-
tration (Table 1).
The pleural infiltration with PMN appeared to corre-
late with an influx of leukocytes into the lung tissue, thus
we investigated the effect of T0901317 on neutrophil
infiltration by measurement of myeloperoxidase activity.
Myeloperoxidase activity was significantly elevated at 4 h
after carrageenan administration in vehicle-treated mice
(Fig. 1e). Treatment with T0901317 significantly attenu-
ated in a dose dependent manner neutrophil infiltration
into the lung tissue (Fig. 1e).
Effects of T0901317 on carrageenan-induced
NO production
No positive staining for iNOS was observed in the lung
tissues obtained from the sham group (Fig. 2a, see den-
sitometry analysis 2e). Immunohistochemical analysis of
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Page 4 of 15Figure 1 Effect of T0901317 on histological alterations of lung tissue 4 h after carrageenan-induced injury and on PMN infiltration in
the lung. Lung sections taken from carrageenan-treated mice pre-treated with vehicle demonstrated edema, tissue injury (b, d) as well as
infiltration of the tissue with neutrophils (see b1). Carrageenan-treated animals pre-treated with T0901317 (20 mg/kg i.p.) (c, d) demonstrated
reduced lung injury and neutrophil infiltration. Original magnification: × 125. Section from a sham animals demonstrating the normal
architecture of the lung tissue (a, d). The figure is representative of at least 3 experiments performed on different experimental days. MPO
activity, index of PMN infiltration, was significantly elevated at 4 h after carrageenan (CAR) administration in vehicle-treated mice (e), if compared
with sham mice (e). T0901317 significantly reduced in a dose dependent manner MPO activity in the lung (e). The figure is representative of at
least 3 experiments performed on different experimental days. Data are expressed as mean ± s.e.m. from n = 10 mice for each group. ND: not
detectable. *P < 0.01 versus sham group. °P < 0.01 versus carrageenan.
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Page 5 of 15lung sections obtained from carrageenan-treated mice
revealed positive staining for iNOS (Fig. 2b, see densito-
metry analysis 2e). T0901317 (20 mg/kg) treatment sig-
nificantly attenuated this iNOS expression (Fig. 2c, see
densitometry analysis 2e). A significant increase in iNOS
expression 4 h after carrageenan injection, as assayed by
Western blot analysis, was also detected in lungs
obtained from mice subjected to carrageenan-induced
pleurisy (Fig. 2d see densitometry analysis 2d1).
T0901317 (20 mg/kg) treatment significantly attenuated
this iNOS expression (Fig. 2d see densitometry analysis
2d1). NO levels were also significantly increased in the
exudate obtained from mice administered carrageenan
(Table 1). Treatment of mice with T0901317 signifi-
cantly reduced in a dose dependent manner NO exu-
dates levels (Table 1). No significant reduction of NO
exudates levels was found in the sham animal.
Effects of T0901317 on carrageenan-induced nitrotyrosine
formation, lipid peroxidation and PARP activation
Immunohistochemical analysis of lung sections obtained
from mice treated with carrageenan revealed positive
staining for nitrotyrosine (Fig. 3b, see densitometry ana-
lysis 3g). In contrast, no positive staining for nitrotyro-
sine was found in the lungs of carrageenan-treated mice,
which had been treated with T0901317 (20 mg/kg) (Fig.
3c, see densitometry analysis 3g). In addition, at 4 hours
after carrageenan-induced pleurisy, MDA levels were
also measured in the lungs as an indicator of lipid per-
oxidation. As shown in Figure 3h, MDA levels were sig-
nificantly increased in the lungs of carrageenan-treated
mice. Lipid peroxidation was significantly attenuated in
a dose dependent manner by the intraperitoneal injec-
tion of T0901317 (Fig. 3h). At the same time point (4 h
after carrageenan administration), lung tissue sections
were taken in order to determine the immunohistologi-
cal staining for poly ADP-ribosylated proteins (an indi-
cator of PARP activation). A positive staining for the
PAR (Fig. 3e, see densitometry analysis 3g) was found
primarily localized in the inflammatory cells present in
the lung tissue from carrageenan-treated mice.
T0901317 treatment reduced the degree of PARP activa-
tion (Figure 3f, see densitometry analysis 3g). Please
note that there was no staining for either nitrotyrosine
(Fig. 3a, see densitometry analysis 3g) or PAR (Fig. 3d,
see densitometry analysis 3g) in lung tissues obtained
from the sham group of mice.
Effects of T0901317 on the release of pro-inflammatory
cytokine induced by carrageenan
When compared to sham animals, injection of carra-
geenan resulted in an increase in the levels of TNF-a
and IL-1b in the pleural exudates (Table 1). The
release of TNF-a and IL-1b was significantly attenu-
ated in a dose dependent manner by treatment with
T0901317 (Table 1). Therefore, we also evaluate the
TNF-a and IL-1b expression in the lung tissues by
immunohistochemical detection. Tissue sections
obtained from vehicle-treated animals at 4 h after car-
rageenan injection demonstrate positive staining for
TNF-a mainly localized in the infiltrated inflammatory
cells, pneumocytes as well as in vascular wall (Fig. 4b,
see densitometry analysis 4d). In contrast, no staining
for TNF-a was found in the lungs of carrageenan-trea-
ted mice that had been treated with T0901317 (Fig. 4c,
see densitometry analysis 4d). Similarly, at 4 hours
after carrageenan injection, positive staining for IL-1b
mainly localized in the infiltrated inflammatory cells
was observed in lung tissue sections obtained from
vehicle-treated animals (Fig. 4f, see densitometry analy-
sis 4h). T0901317 treatment reduced the degree of
IL-1b expression (Fig. 4g, see densitometry analysis
4h). Please note that there was no staining for either
TNF-a (Fig. 4a, see densitometry analysis 4d) or IL-1b
(Fig. 4e, see densitometry analysis 4h) in lung tissues
obtained from the sham group of mice.
Table 1 Effect of T0901317 on Carrageenan(CAR)-induced inflammation, TNF-a, IL-1b and Nitrite Nitrate production in
the pleural exudate
Volume Exudate
(ml)
PMNs infiltration
(million cells/mouse)
TNF-a
(pg/ml)
IL-1b
(pg/ml)
Nitrite/nitrate
(nmol/mouse)
Sham + Vehicle 0.06 ± 0.03 0.4 ± 0.12 8.0 ± 0.6 6.0 ± 1.3 12 ± 1
Sham + T0901317
(20 mg/kg)
0.07 ± 0.05 0.5 ± 0.18 9.0 ± 0.7 7.0 ± 2.2 11 ± 1.2
CAR + Vehicle 1.2 ± 0.12* 9.5 ± 0.9* 55 ± 4.5* 151 ± 12* 135 ± 18*
CAR + T0901317
(20 mg/kg)
0.20 ± 0.1° 2.5 ± 0.18° 19 ± 1.5° 35 ± 7.5° 40 ± 3.5°
CAR + T0901317
(10 mg/kg)
0.41 ± 0.14° 4.5 ± 0.22° 29 ± 1.6° 65 ± 6.8° 74 ± 4.5°
CAR + T0901317
(5 mg/kg)
0.90 ± 0.15
# 7.5 ± 0.35
# 32 ± 2.5
# 95 ± 4.5
# 100 ± 2.4
#
Data are means ± s.e. means of 10 mice for each group. *P < 0.01 versus sham. °P < 0.01 versus carrageenan
#P < 0.05 versus carrageenan.
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Page 6 of 15Figure 2 Effect of T0901317 on carrageenan-induced iNOS expression and NO formation in the lung. Lung sections taken from
carrageenan-treated mice pre-treated with vehicle showed positive staining for iNOS, localized mainly in inflammatory cells (b, e). The degree of
positive staining for iNOS was markedly reduced in tissue sections obtained from mice pre-treated with 20 mg/kg T0901317 (c, e). Original
magnification: × 125. Lung sections taken from sham mice showed no staining for iNOS (a, e). The figure is representative of at least 3
experiments performed on different experimental days. A significant increase in iNOS (d, d1) expression, assayed by Western blot analysis, was
detected in lungs obtained from mice subjected to carrageenan-induced pleurisy, if compared with lung from sham mice (d, d1). Pre-treatment
with T0901317 20 mg/kg significantly attenuated iNOS (d, d1) expression in the lung tissues. A representative blot of lysates obtained from 5
animals per group is shown and densitometry analysis of all animals is reported. The results in panel d1 are expressed as mean ± s.e.m. from n
= 5/6 lung tissues for each group. ND: not detectable. *P < 0.01 versus sham group. °P < 0.01 versus carrageenan.
Crisafulli et al. Respiratory Research 2010, 11:19
http://respiratory-research.com/content/11/1/19
Page 7 of 15Effect of T0901317 on IB-a degradation and NF-B p65
activation
We evaluated IB-a degradation and nuclear NF-B
p65 expression by Western blot analysis to investigate
the cellular mechanisms whereby treatment with
T0901317 attenuates the development of acute lung
injury. Basal expression of IB-a was detected in lung
samples from sham-treated animals, whereas IB-a
levels were substantially reduced in lung tissues obtained
from vehicle-treated animals at 4 h after carrageenan
injection (Fig. 5a, see densitometry analysis 5a1).
T0901317 (20 mg/kg) treatment prevented carrageenan-
induced IB-a degradation (Fig. 5a, see densitometry
analysis 5a1). Moreover, NF-B p65 levels in the lung
nuclear fractions were also significantly increased at 4 h
after carrageenan injection compared to the sham-trea-
ted mice (Fig. 5b, see densitometry analysis 5b1).
T0901317 treatment significantly reduced the levels of
NF-B p65, as shown in Fig. 5b (see densitometry analy-
sis 5b1).
T0901317 modulates expression of Fas ligand after
carrageenan injection
Immunohistological staining for Fas ligand in the lung
was also determined at 4 h after carrageenan injection.
Lung sections from sham-treated mice did not stain for
Fas ligand (Fig. 6a, see densitometry analysis 6d),
whereas lung sections obtained from carrageenan-trea-
ted mice exhibited positive staining for Fas ligand
(Fig. 6b, see densitometry analysis 6d) primarily
Figure 3 Effect of T0901317 on carrageenan-induced nitrotyrosine formation and lipid peroxidation and PARP activation in the lung.
No staining for nitrotyrosine is present in lung section from sham mice (a, g). Lung sections taken from carrageenan-treated mice pre-treated
with vehicle showed positive staining for nitrotyrosine, localized mainly in inflammatory cells (b, g). There was a marked reduction in the
immunostaining for nitrotyrosine in the lungs of carrageenan-treated mice pre-treated with 20 mg/kg T0901317 (c, g). Malondialdehyde (MDA)
levels, an index of lipid peroxidation, were significantly increased in lung tissues 4 h after carrageenan (CAR) administration (h), if compared with
lung from sham mice (h). T0901317 significantly reduced in a dose dependent manner the carrageenan-induced elevation of MDA tissues levels
(h). Lung sections taken from carrageenan-treated mice pre-treated with vehicle showed positive staining for PAR (e, g). There was a marked
reduction in the immunostaining for PAR in the lungs of carrageenan-treated mice pre-treated with 20 mg/kg T0901317 (f, g). Lung section from
sham mice showed no staining for PAR (d, g). The figure is representative of at least 3 experiments performed on different experimental days.
Data are expressed as mean ± s.e.m. from n = 10 mice for each group. ND: not detectable *P < 0.01 versus sham group. °P < 0.01 versus
carrageenan.
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Page 8 of 15localized in the inflammatory cells present in the lung
tissue. T0901317 (20 mg/kg) treatment reduced the
degree of positive staining for FAS Ligand in the lung
tissues (Fig. 6c, see densitometry analysis 6d).
Effects of T0901317 on apoptosis in lung tissues after
carrageenan-induced pleurisyTo investigate whether
acute lung inflammation is associated with apoptotic cell
death we measured TUNEL-like staining in lung tissues.
At 4 hours after carrageenan administration, lung tissues
demonstrated a marked appearance of dark brown
apoptotic cells and intercellular apoptotic fragments
(Fig. 6f, see 6h). In contrast, no apoptotic cells or frag-
ments were observed in the tissues obtained from carra-
geenan-mice treated with T0901317 (Fig. 6g, see 6h).
Similarly, no apoptotic cells were observed in lungs of
sham-treated mice (Fig. 6e, see 6h).
Western blot analysis and immunohistochemistry for Bax
and Bcl-2
The presence of Bax in lung homogenates was investi-
gated by Western blot 4 hours after carrageenan admin-
istration. No Bax expression was detected in lung tissues
Figure 4 Effect of T0901317 on carrageenan-induced pro-inflammatory cytokine release in the lung. Lung sections taken from
carrageenan-treated mice pre-treated with vehicle showed positive staining for TNF-a and IL-1b (b, d and f, h). There was a marked reduction in
the immunostaining for TNF-a and IL-1b in the lungs of carrageenan-treated mice pre-treated with 20 mg/kg T0901317 (c, d and g, h). No
staining for either TNF-a (a, d) or IL-1b (e, h) in lung tissues obtained from the sham group of mice. The figure is representative of at least 3
experiments performed on different experimental days. ND: not detectable. Data are expressed as mean ± s.e.m. from n = 10 mice for each
group. *P < 0.01 versus sham group. °P < 0.01 versus carrageenan.
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Page 9 of 15obtained from sham-treated animals (Fig. 7Ae, see den-
sitometry analysis 7Ae1). Bax levels were substantially
increased in the lung tissues from carrageenan-treated
mice (Fig. 7Ae, see densitometry analysis 7Ae1). On the
contrary, T0901317 (20 mg/kg) treatment prevented the
carrageenan-induced Bax expression (Fig. 7Ae, see den-
sitometry analysis 7Ae1).
To detect Bcl-2 expression, whole extracts from lung
tissues of mice were also analyzed by Western blot ana-
lysis. A basal level of Bcl-2 expression was detected in
lung tissues from sham-treated mice (Fig. 7Be, see
densitometry analysis 7Be1). At 4 hours after carragee-
nan administration, Bcl-2 expression was significantly
reduced (Fig. 7Be, see densitometry analysis 7Be1).
Treatment of mice with T0901317 (20 mg/kg) signifi-
cantly attenuated carrageenan-induced inhibition of Bcl-
2 expression (Fig. 7Be, see densitometry analysis 7Be1).
Lung samples were also collected 4 hours after carra-
geenan administration in order to determine the immu-
nohistological staining for Bax and Bcl-2. Lung tissues
taken from sham-treated mice did not stain for Bax
(Fig. 7Aa, see densitometry analysis 7Ad) whereas lung
Figure 5 Representative Western blots showing the effects of T0901317 on IB-a degradation and nuclear NF- Bp65 expression after
carrageenan (CAR) injection. Basal expression of IB-a was detected in lung samples from sham-treated animals, whereas IB-a levels were
substantially reduced in lung tissues obtained from vehicle-treated animals at 4 h after carrageenan injection (a, a1). T0901317 (20 mg/kg)
treatment prevented carrageenan-induced IB-a degradation (a, a1). NF-B p65 levels in the lung nuclear fractions were also significantly
increased at 4 h after carrageenan injection compared to the sham-treated mice (b, b1). T0901317 treatment significantly reduced the levels of
NF-B p65 (b, b1). A representative blot of lysates obtained from 5 animals per group is shown and densitometry analysis of all animals is
reported. The results in panel a1 and b1 are expressed as mean ± s.e.m. from n = 5/6 lung tissues for each group. ND: not detectable. *P < 0.01
versus sham group. °P < 0.01 versus carrageenan.
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ited positive staining for Bax (Fig. 7Ab, see densitometry
analysis 7Ad). T0901317 (20 mg/kg) treatment reduced
the degree of positive staining for Bax in the lung of
mice subjected to carrageenan-induced pleurisy (Fig.
7Ac, see densitometry analysis 7Ad).
In addition, lung sections from sham-treated mice
demonstrated positive staining for Bcl-2 (Fig. 7Ba, see den-
sitometry analysis 7Bd) whereas in carrageenan-treated
mice Bcl-2 staining was significantly reduced (Fig. 7Bb, see
densitometry analysis 7Bd). T0901317 (20 mg/kg) treat-
ment significantly attenuated the loss of positive staining
for Bcl-2 in mice subjected to carrageenan-induced
pleurisy (Fig. 7Bc, see densitometry analysis 7Bd).
Discussion
This study provides the evidence that T0901317 modu-
lates: (i) the development of carrageenan-induced
Figure 6 Effect of T0901317 on carrageenan-induced Fas ligand expression and on apoptosis as measured by TUNEL like staining.
Positive staining for Fas ligand was observed in lung sections taken from carrageenan-treated mice pre-treated with vehicle (b, d) compared to
sham-operated mice (a, d). In contrast, T0901317 (20 mg/kg) treatment reduced the degree of positive staining for FAS Ligand in the lung
tissues (c, d). Positive TUNEL staining was observed in lung sections taken from carrageenan-treated mice pre-treated with vehicle (f, h). In
contrast, tissue obtained from carrageenan treated mice pre-treated with T0901317 (20 mg/kg) demonstrated no apoptotic cells or fragments (g,
h). Almost no apoptotic cells were observed in lungs of sham mice (e, h). The figure is representative of at least 3 experiments performed on
different experimental days. ND: not detectable. Data are expressed as mean ± s.e.m. from n = 10 mice for each group. *P < 0.01 versus sham
group. °P < 0.01 versus carrageenan.
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Page 11 of 15pleurisy, (ii) the infiltration of the lung with PMNs, (iii)
the degree of lipid peroxidation in the lung, (iv) the
expression of TNF-a and IL-1b, (v) iNOS expression (by
immunohistochemistry and western blot analysis), (vi)
the nitration of tyrosine residues, (vii) NF-Be x p r e s s i o n
(viii) Fas-ligand, (ix) apoptosis, (x) Bax and Bcl-2 expres-
sion and (xi) the degree of lung injury caused by injection
of carrageenan. All of these findings support the view
that T0901317 attenuates the degree of acute inflamma-
tion in the mouse. What, then, is the mechanism by
which T0901317 reduces acute inflammation?
Liver × receptors (LXRs), a family of nuclear recep-
tors, heterodimerize with retinoid × receptor (RXR) and
bind specific elements (LXREs) characterized by direct
repeats spaced by four nucleotides [29]. The LXR signal-
ing pathway is thought to play an important role in lipid
metabolism [30].
NF-B plays a central role in the regulation of many
genes responsible for the generation of mediators or
proteins in inflammation. These include the genes for
examples: TNF-a, IL-1b, iNOS and COX-2.
Recent data suggests that the LXR pathway antago-
nizes the NF-B signaling pathway and inhibits the
expression of inflammatory genes downstream of NF-B
[31]. Moreover, Joseph and colleagues have showed that
a synthetic LXR agonist repressed the transcriptional
Figure 7 Effect of T0901317 on carrageenan-induced Bax and Bcl-2 expression in the lung. Representative Western blots showing no Bax
expression in lung tissues obtained from sham-treated animals (Ae, Ae1). Bax levels were increased in the lung tissues from carrageenan-treated
mice (Ae, Ae1). T0901317 (20 mg/kg) treatment prevented the carrageenan-induced Bax expression (Ae, Ae1). A basal level of Bcl-2 expression
was detected in lung tissues from sham-treated mice (Be, Be1). At 4 hours after carrageenan administration, Bcl-2 expression was significantly
reduced (Be, Be1). Treatment of mice with T0901317 (20 mg/kg) significantly attenuated carrageenan-induced inhibition of Bcl-2 expression (Be,
Be1). A representative blot of lysates obtained from 5 animals per group is shown and densitometry analysis of all animals is reported. The
results in panel Ae1 and Be1 are expressed as mean ± s.e.m. from n = 5/6 lung tissues for each group. *P < 0.01 versus sham group. °P < 0.01
versus carrageenan. Lung sections taken from carrageenan-treated mice pre-treated with vehicle showed positive staining for Bax (Ab, Ad)
localized mainly in the inflammatory cells. The degree of positive staining for Bax was markedly reduced in lung sections obtained from mice
pre-treated with 20 mg/kg T0901317 mice (Ac, Ad). Positive staining for Bcl-2 was observed in lung sections taken from sham mice (Ba, Bd). The
degree of positive staining for Bcl-2 was markedly reduced in lung sections obtained from carrageenan-mice treated with vehicle (Bb, Bd). Pre-
treatment with T0901317 20 mg/kg significantly attenuated the reduction in Bcl-2 expression caused by carrageenan (Bc, Bd). The figure is
representative of at least 3 experiments performed on different experimental days. ND: not detectable Data are expressed as mean ± s.e.m. from
n = 10 mice for each group. *P < 0.01 versus sham group. °P < 0.01 versus carrageena.
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Page 12 of 15activity of NF-B, but not that of AP-1 in the presence
of LXR, using a luciferase reporter assay [13]. Moreover,
it has been, also, shown that the LXR agonist inhibits
NF-B-induced MMP-9 gene expression through LXR
activation without affecting NF-B DNA binding activity
[32]We report here that carrageenan caused a significant
increase in the IB-a degradation in the lung tissues at
4 h, whereas treatment with the LXR agonist T0901317
significantly reduced this phosphorylation. Moreover, we
also demonstrate that the selective and potent LXR ago-
nist T0901317 inhibited the nuclear translocation of p65
in the lung tissues at 4 h after carrageenan administra-
tion. Taken together, the balance between pro-inflam-
matory and pro-survival roles of NF-Bm a yd e p e n do n
the phosphorylation status of p65, and LXR receptor
m a yp l a yac e n t r a lr o l ei nt h i sp r o c e s s .H o w e v e r ,t h e
reasons for the apparent discrepancies in the modula-
tory effects of LXR receptor on NF-B activity remain
to be fully elucidated.
There is good evidence that TNF-a and IL-1b help
to propagate the extension of a local or systemic
inflammatory process. Various studies have clearly
reported that inhibition of TNF-a formation signifi-
cantly prevent the development of the inflammatory
process [33]. This study demonstrates that T0901317
attenuates the TNF-a and IL-1b production in the
pleural exudates of carrageenan-treated mice. There-
fore, the inhibition of the production of TNF-a and
IL-1b by T0901317 described in the present study is
most likely attributed to the inhibitory effect the acti-
vation of NF-B. Indeed, the effects of TO-901317 on
TNFa p a r a l l e lt h o s ep r e v i o u s l yr e p o r t e di nar o d e n t
LPS lung injury model [10].
Furthermore, recently it has been demonstrated the
expression of LXR in alveolar macrophages, alveolar
type II cells, and PMNs and proceed to show potent
anti-inflammatory and ant host defense effects of syn-
thetic LXR agonists in the lung [10]. These anti-
inflammatory and ant host defense effects share in
common impairment of PMN recruitment to the
lung [10].
In agreement with this previous observation, in the
present study we have also demonstrated that T0901317
treatment significantly reduced the leukocyte infiltration
as assessed by the specific granulocyte enzyme MPO at
4 hour after carrageenan administration. Activation and
accumulation of leukocytes is one of the initial events of
tissue injury due to release of oxygen free radicals, ara-
chidonic acid metabolites and lysosomal proteases
[20,34].
Enhanced formation of NO by iNOS may contribute
to the inflammatory process [20,35]. This study demon-
strates that T0901317 attenuates the expression of iNOS
in the lung in carrageenan-treated mice. Therefore, the
inhibition of iNOS expression by T0901317 described in
the present study is most likely attributed to the inhibi-
tory effect the activation of NF-B. Moreover, the
observed effect of T0901317 on iNOS expression is in
agreement with a previous study in which Yasuda and
colleagues have clearly described that another synthetic
LXR agonist, 22R-HC inhibits NO production and iNOS
expression in LPS-activated RAW264.7 macrophages
suggesting that 22R-HC can negatively regulate excess
NO during an inflammatory response, even after the
onset of inflammation [31].
T h e r ei sal a r g eb o d yo fe v i d e n c es h o w i n gt h a tt h e
production of reactive oxygen and nitrogen species play
key roles in acute inflammation [36].
Nitrotyrosine formation, along with its detection by
immunostaining, was initially proposed as a relatively
specific marker for the detection of the endogenous for-
mation “footprint” of peroxynitrite. There is, however,
recent evidence that certain other reactions can also
induce tyrosine nitration e.g. reaction of nitrite with
hypoclorous acid and the reaction of MPO with hydro-
gen peroxide can lead to the formation of nitrotyrosine.
Increased nitrotyrosine staining is therefore considered
as an indicator of “increased nitrosative stress” rather
than a specific marker of the generation of peroxynitrite.
We report here that carrageenan caused a significant
increase in the nitrotyrosine formation and lipid peroxi-
dation in the lung tissues at 4 h, which is significantly
reduced by the treatment with the LXR agonist
T0901317.
Therefore, the inhibition of nitrotyrosine formation
and lipid peroxidation by T0901317 described in the
present study is most likely attributed to the inhibitory
effect the expression of iNOS by T09013178.
Generation of ROS have been implicated in induc-
tion of cell death and inflammation in the paw and
lung tissues after carrageenan injection [20,37].
Furthermore, cell death induced by reactive oxygen
species (ROS) depends on FasL expression mediated by
redox sensitive activation of NF-B[ 3 8 ] .F a s Lp l a y sa
central role in apoptosis induced by a variety of chemi-
cal and physical insults [39]. Recently it has been point
out that Fas-Fas ligand (FasL) signaling plays a central
role in acute inflammation (e.g. acute lung injury)
[40,41]. We confirm here that the inflammatory pro-
cess (carrageenan-induced pleurisy) leads to a substan-
tial activation of FasL in the lung tissues which likely
contribute in different capacities to the evolution of
acute inflammation. In the present study, we found
that FasL activation was significantly reduced in lungs
from mice treated with T0901317. Moreover, in the
present study we have also demonstrated that treat-
ment with T0901317 attenuates the degree of apopto-
sis, measured by TUNEL detection kit, in the lung at
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Page 13 of 154 h after carrageenan administration. On the contrary
some evidence have shown that chronic LXR activation
is known to induce apoptosis in different cells line e.g.
pancreatic b-cells [42].
Therefore, in the present study, we have identified
pro-apoptotic transcriptional changes, including up-reg-
ulation of pro-apoptotic Bax and down-regulation of
anti-apoptotic Bcl-2, using western blot assay and by
immunohistochemical staining. We report in the pre-
sent study for the first time that the treatment with the
LXR agonist T0901317 in acute lung injury documents
features of apoptotic cell death after carrageenan
administration, suggesting that protection from apopto-
sis may be a prerequisite for anti-inflammatory
approaches. In particular, we demonstrated that the
treatment with T0901317 lowers the signal for Bax in
treated group when compared with lung sections
obtained from carrageenan-treated mice; while on the
contrary, the signal is much more express for Bcl-2 in
the LXR agonist T0901317 treated mice than in carra-
geenan-treated mice. This means that the LXR agonist
T0901317 by inhibiting NF-Bp r e v e n t st h el o s so ft h e
anti-apoptotic way and reduced the pro-apoptotic path-
way activation with a mechanism still to discover.
Taken together, the results of the present study enhance
our understanding of the role of the LXR receptor in
the pathophysiology of acute inflammation. Our results
imply that LXR agonists may be useful in the therapy of
inflammation.
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